Holen Sie sich die Stockscreener-App
8.10
0.87%
0.07
Handel nachbörslich:
8.15
0.05
+0.62%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.03
Offen:
$8.1
24-Stunden-Volumen:
3.58M
Relative Volume:
0.89
Marktkapitalisierung:
$1.33B
Einnahmen:
$1.12B
Nettoeinkommen (Verlust:
$440.30M
KGV:
3.4026
EPS:
2.3805
Netto-Cashflow:
$-251.02M
1W Leistung:
+2.27%
1M Leistung:
+5.19%
6M Leistung:
+5.33%
1J Leistung:
+29.19%
1-Tages-Spanne:
$7.812
$8.16
1-Wochen-Bereich:
$7.71
$8.355
52-Wochen-Spanne:
$5.80
$11.97
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.10 | 1.32B | 1.12B | 440.30M | -251.02M | 2.3805 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Eingeleitet | Citigroup | Sell |
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Novavax earnings in focus: Safety edge meets steep revenue test By Investing.com - Investing.com Nigeria
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates? - TradingView
Attachment - GlobeNewswire
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Novavax, Inc. (NVAX) A Good Stock To Buy Now? - Insider Monkey
Vanguard reports 8.31M-share stake in Novavax (NVAX) - Stock Titan
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Novavax investors get first-quarter 2026 results at 8:30 a.m. May 6 - Stock Titan
Novavax, Inc. (NVAX) is attracting investor attention: Here is what you should know - MSN
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax (NVAX) director exercises RSUs for 9,520 common shares - Stock Titan
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Novavax Q2 2025 Earnings Preview - MSN
Bank of America reports 4.1% Novavax stake (NASDAQ: NVAX) - Stock Titan
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NASDAQ: NVAX) details 2026 proxy, board slate and equity share increases - Stock Titan
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
NVAX stock rises overnight ahead of Q4 print with Pfizer tailwinds — analyst warns of 20% crash - MSN
Novavax Soars After Covid Vaccine Secures Full FDA Approval - MSN
Avoiding Lag: Real-Time Signals in (NVAX) Movement - Stock Traders Daily
Novavax Q3 2025 Earnings Preview - MSN
Cash-Rich Stocks: 10x Genomics, Novavax, and Powell Analysis | April 2026News and Statistics - IndexBox
Is Novavax (NVAX) Now Pricing In Too Much Risk After Its Recent Volatility - Yahoo Finance
Therapeutics Stocks Q4 Earnings: AbbVie and Novavax Performance Analysis as of April 2026News and Statistics - IndexBox
Novavax, Inc. (NVAX) PT Increased as B. Riley Sees Governance-Driven Catalysts Ahead - Insider Monkey
FY2028 EPS Estimates for Novavax Cut by Zacks Research - MarketBeat
1 Cash-Heavy Stock to Target This Week and 2 We Ignore - The Globe and Mail
Novavax (NVAX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Earnings snapshot: Novavax tops Q2 estimates; raises full-year outlook - MSN
5 Most Undervalued Healthcare Stocks to Buy Now - Insider Monkey
Is Novavax (NVAX) stock a good investment this year | Novavax Inc. posts 122% EPS beat vs expected lossProfit Guidance - Xã Thanh Hà
US CDC will not publish report showing COVID vaccine effectiveness - Reuters
COVID vaccine report on cutting hospital visits blocked from publication in CDC journal - Seeking Alpha
Will Acute Care Strength Help Universal Health Offset Q1 Rising Costs? - TradingView
Will Higher Costs & Lower Occupancy Impact HCA's Q1 Earnings? - TradingView
Therapeutics Q4 Earnings: Novavax (NASDAQ:NVAX) Simply the Best - Yahoo Finance
H.C. Wainwright reiterates Novavax stock rating on vaccine study By Investing.com - Investing.com India
H.C. Wainwright reiterates Novavax stock rating on vaccine study - Investing.com
Is Shah Capital’s Criticism of Novavax Fair? A Wall Street Analyst Weighs In - MedCity News
Novavax’s COVID vaccine becomes 4th available for use in Japan - 朝日新聞
Novavax Urged to Probe Studies Using Monkeys From Filthy Lab After PETA Exposé - PETA
Novavax (NVAX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Novavax (NVAX) EVP R&D discloses options, RSUs and shares on Form 3 - Stock Titan
Discipline and Rules-Based Execution in NVAX Response - Stock Traders Daily
Novavax Inc stock (US6707721049): Is its vaccine pipeline strong enough to unlock new upside? - AD HOC NEWS
SHAH CAPITAL MANAGEMENT Increases Stake in Novavax Inc - GuruFocus
Novavax Inc stock (US6707721049): Is its vaccine pivot strong enough to unlock new upside? - AD HOC NEWS
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):